3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01530 3SBIO

Closed 03-27 16:08:22

12.000

+1.180

+10.91%

High12.400	Low10.580	Vol87.08M
Open10.840	D1 Closing10.820	Amplitude16.82%
Mkt Cap28.75B	Tradable Cap28.75B	Total Shares2.40B
T/O1.03B	T/O Rate3.64%	Tradable Shares2.40B
P/B1.74	ROE12.84%	EPS0.92
52wk High12.400	52wk Low5.290	P/E13.05
Dividend0.24	Div.Yield0.02	ROA6.68%

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"3SBIO","latestPrice":12,"timestamp":1743062902012,"preClose":10.82,"halted":0,"volume":87079878,"delay":0,"floatShares":2395573912,"shares":2395573912,"eps":0.9192455441848891,"marketStatus":"Closed","change":1.18,"latestTime":"03-27 16:08:22","open":10.84,"high":12.4,"low":10.58,"amount":1031349401,"amplitude":0.168207,"askPrice":12.02,"askSize":34000,"bidPrice":12,"bidSize":183000,"shortable":3,"etf":0,"ttmEps":0.9085566425083207,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743125400000},"marketStatusCode":5,"adr":0,"exchange":"SEHK","adjPreClose":10.82,"dividendRate":0.020236,"openAndCloseTimeList":[[1743039000000,1743048000000],[1743051600000,1743062400000]],"volumeRatio":1.414709,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530/tweets","defaultTab":"tweets","newsList":[{"id":"2522384288","title":"3SBio's 2024 Profit Jumps 35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522384288","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522384288?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 17:19","pubTimestamp":1742980795,"startTime":"0","endTime":"0","summary":"3SBio's  attributable profit rose 35% to 2.09 billion yuan in 2024 from 1.55 billion yuan in 2023, according to a Tuesday filing with the Hong Kong bourse.Earnings per share at the biopharmaceutical company increased to 0.85 yuan from 0.62 yuan a year earlier.  Analysts at Visible Alpha estimated EPS per share at 0.83 yuan.Revenue grew 17% to 9.11 billion yuan from 7.82 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 8.90 billion yuan.The company declared a final dividend of HK$0.25 per share, payable Aug. 15 to shareholders on record as of July 25.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1161","BK1593","01530"],"gpt_icon":0},{"id":"1107392270","title":"Stock Track | 3SBIO Soars 5.19% Pre-Market on Strong Financial Results and Dividend Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1107392270","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107392270?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 09:52","pubTimestamp":1742953961,"startTime":"0","endTime":"0","summary":"3SBIO  stock is soaring 5.19% in pre-market trading on Wednesday, following the company's announcement of robust financial results for the fiscal year and a final dividend declaration.The Chinese biopharmaceutical company reported impressive financial metrics, including revenue of RMB 9,108 million and a gross profit of RMB 7,828.4 million. The company maintained a high gross margin of 86%, demonstrating strong operational efficiency. 3SBIO's EBITDA reached RMB 3,173.8 million, with adjusted EBI","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"gpt_icon":0},{"id":"1137148111","title":"Stock Track | 3SBIO Soars 5.19% Following Strong Financial Results and Dividend Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1137148111","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137148111?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 09:52","pubTimestamp":1742953960,"startTime":"0","endTime":"0","summary":"3SBIO , a leading Chinese biopharmaceutical company, saw its stock price surge 5.19% in pre-market trading on Wednesday following the release of impressive full-year financial results and the announcement of a final dividend.The company reported robust financial performance for the fiscal year, with revenue reaching RMB 9,108 million. 3SBIO demonstrated strong profitability, posting a basic earnings per share  of RMB 0.86 and maintaining an exceptionally high gross margin of 86%. The gross profi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | 3SBIO Soars 5.19% Following Strong Financial Results and Dividend Announcement","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01530"],"gpt_icon":0},{"id":"2522006008","title":"BRIEF-3SBIO Announces Final Dividend Of HKD25 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522006008","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522006008?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 23:15","pubTimestamp":1742915757,"startTime":"0","endTime":"0","summary":"BRIEF-3SBIO Announces Final Dividend Of HKD25 Cents Per ShareMarch 25  - 3SBio Inc 1530.HK:FY BASIC EPS RMB 0.86FY GROSS MARGIN 86%FY REVENUE RMB 9,108 MILLIONFY GROSS PROFIT RMB 7,828.4 MILLIONFY EBITDA RMB 3,173.8 MILLIONFY ADJUSTED EBITDA RMB 3,402.3 MILLIONFINAL DIVIDEND OF HKD25 CENTS PER SHAREFurther company coverage: 1530.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXDA38C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1593","BK1583","BK1161"],"gpt_icon":0},{"id":"2522302440","title":"3SBio FY Adjusted Ebitda RMB 3,402.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2522302440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522302440?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:56","pubTimestamp":1742903775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXDA38C0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","01530","BK1583","BK1161"],"gpt_icon":0},{"id":"2522244710","title":"3SBio FY Basic EPS RMB 0.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2522244710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522244710?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:56","pubTimestamp":1742903775,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXDA38C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01530","BK1583","BK1593","BK1161"],"gpt_icon":0},{"id":"2522024474","title":"3SBio FY Gross Margin 86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522024474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522024474?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:56","pubTimestamp":1742903775,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nPLXDA38C0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2518737255","title":"3SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2518737255","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518737255?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 06:21","pubTimestamp":1741645317,"startTime":"0","endTime":"0","summary":"Despite an already strong run, 3SBio Inc. ( HKG:1530 ) shares have been powering on, with a gain of 27% in the last...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-inc-hkg1530-soars-27-but-its-a-story-of-risk-vs-reward","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","BK4139","01530","TRSBF","BK1593"],"gpt_icon":0},{"id":"2511518808","title":"3SBio Inc.'s (HKG:1530) Stock Is Going Strong: Have Financials A Role To Play?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511518808","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511518808?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 12:21","pubTimestamp":1739420484,"startTime":"0","endTime":"0","summary":"Most readers would already be aware that 3SBio's (HKG:1530) stock increased significantly by 12% over the past month...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/3sbio-incs-hkg1530-stock-is-going-strong-have-financials-a-r-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","TRSBF","BK1593","01530","BK1161","BK4139"],"gpt_icon":0},{"id":"2503058695","title":"BRIEF-3SBio Announces Cooperation With Duality Biologics In Respect Of Her2 Adc Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503058695","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503058695?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 23:10","pubTimestamp":1736781009,"startTime":"0","endTime":"0","summary":"BRIEF-3SBio Announces Cooperation With Duality Biologics In Respect Of Her2 Adc DrugJan 13 (Reuters) - 3SBio Inc 1530.HK:COOPERATION BETWEEN 3SBIO INC. AND DUALITY BIOLOGICS IN RESPECT OF HER2 ADC DRUGFurther company coverage: 1530.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O801K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1593","BK1583","BK1161"],"gpt_icon":0},{"id":"2503303106","title":"3SBio Unit Gets Commercialization Rights for Duality Biologics' Cancer Drug in China, Hong Kong, Macau","url":"https://stock-news.laohu8.com/highlight/detail?id=2503303106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503303106?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 20:16","pubTimestamp":1736770586,"startTime":"0","endTime":"0","summary":"3SBio's  unit Shenyang Sunshine Pharmaceutical will obtain the commercialization rights for HER2 ADC drug DB-1303 from Duality Biologics  for various indications in China, Hong Kong, and Macau, a Monday Hong Kong bourse filing said.Duality Biologics is a clinical-stage innovative biopharmaceutical company mainly engaged in the research and development of antibody-drug conjugates therapeutic agents for the treatment of patients with cancer or autoimmune diseases.HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that can be found on the surface of some cancer cells.DB-1303 is designed to treat cancers that have high levels of HER2 expression, such as certain types of breast, gastric, and endometrial cancers. The drug combines an anti-HER2 monoclonal antibody with a topoisomerase I inhibitor, which helps to disrupt the cancer cells' DNA and inhibit their growth.Shenyang Sunshine will make upfront fees and research, development, and sales milestone payments as part of the coo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01530","BK1593","BK1583","BK1161"],"gpt_icon":0},{"id":"2503378460","title":"3SBio -  Cooperation Between 3SBio Inc. and Duality Biologics in Respect of Her2 ADC Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503378460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503378460?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 17:17","pubTimestamp":1736759863,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O801K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1593","01530"],"gpt_icon":0},{"id":"2492904013","title":"3SBio Cancels All Treasury Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2492904013","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492904013?lang=en_us&edition=full_marsco","pubTime":"2024-12-18 19:50","pubTimestamp":1734522657,"startTime":"0","endTime":"0","summary":"3SBio  canceled 21,227,000 shares held in treasury after they were repurchased through a series of repurchases under the company's 2023 and 2024 repurchase mandates, a Wednesday Hong Kong bourse filing said.The canceled shares represent 0.89% of the total number of issued shares of the company.After the cancellation, the company no longer has any shares held in treasury while it still has 2,395,573,912 shares in issue.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["US5Y.BOND","US10Y.BOND","US30Y.BOND","US3Y.BOND","BK1583","US6M.BOND","01530","US2Y.BOND","BK1593","US12M.BOND","US7Y.BOND","BK1161"],"gpt_icon":0},{"id":"2486025176","title":"3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2486025176","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486025176?lang=en_us&edition=full_marsco","pubTime":"2024-11-26 17:02","pubTimestamp":1732611731,"startTime":"0","endTime":"0","summary":"3SBio's  unit Shenyang Sunshine Pharmaceutical has agreed to obtain the exclusive commercialization rights of Sunshine Lake Pharma's clifutinib besylate for specific indications in Mainland China, a Monday bourse filing said.Under the contract, Shenyang Sunshine Pharmaceutical will pay Sunshine Lake Pharma an initial payment as well as certain R&D and sales milestone payments.Sunshine Lake Pharma will continue to be responsible for the research and development, registration, production, and other works related to the drug.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1161","BK1593","01530"],"gpt_icon":0},{"id":"2486709950","title":"BRIEF-3SBio Announces Cooperation Between Shenyang Sunshine And Sunshine Lake Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486709950?lang=en_us&edition=full_marsco","pubTime":"2024-11-25 18:21","pubTimestamp":1732530114,"startTime":"0","endTime":"0","summary":"Nov 25 (Reuters) - 3SBio Inc   :   * COOPERATION BETWEEN SHENYANG SUNSHINE AND SUNSHINE LAKE PHARMA IN RESPECT OF CLIFUTINIB BESYLATE Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01530","BK1593"],"gpt_icon":0},{"id":"2486706614","title":"3SBio - Cooperation Between Shenyang Sunshine and Sunshine Lake Pharma in Respect of Clifutinib Besylate","url":"https://stock-news.laohu8.com/highlight/detail?id=2486706614","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486706614?lang=en_us&edition=full_marsco","pubTime":"2024-11-25 18:01","pubTimestamp":1732528898,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nFWN3MV01V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01530","BK1583","BK1593"],"gpt_icon":0},{"id":"2486657053","title":"The five-year underlying earnings growth at 3SBio (HKG:1530) is promising, but the shareholders are still in the red over that time","url":"https://stock-news.laohu8.com/highlight/detail?id=2486657053","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486657053?lang=en_us&edition=full_marsco","pubTime":"2024-11-25 15:08","pubTimestamp":1732518527,"startTime":"0","endTime":"0","summary":"In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1530/3sbio-shares/news/the-five-year-underlying-earnings-growth-at-3sbio-hkg1530-is-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01530"],"gpt_icon":0},{"id":"2483807603","title":"BRIEF-3SBio Says CFO Increased Shareholding In Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2483807603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483807603?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 23:10","pubTimestamp":1731597016,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - 3SBio Inc   :   * SINCE 1 JAN TO 14 NOV, CFO INCREASED SHAREHOLDING IN CO BY AGGREGATE OF 3.0 MILLION ORDINARY SHARES AT HKD5.99 PER SHARE Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","BK1593","BK1161","BK1583"],"gpt_icon":0},{"id":"2483875292","title":"3SBio's CFO Boosts Stakeholding","url":"https://stock-news.laohu8.com/highlight/detail?id=2483875292","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483875292?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 19:55","pubTimestamp":1731585312,"startTime":"0","endTime":"0","summary":"3SBio's (HKG:1530) Chief Financial Officer HE Xiang bought an additional 3 million shares in the company since Jan. 1, at an average price of HK$5.99 per share, a Thursday bourse filing said.The shares represent roughly 0.12% of the biopharmaceutical company's total issued shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2483857827","title":"3SBio - Since 1 Jan to 14 Nov, CFO Increased Shareholding in Co by Aggregate of 3.0 Mln Ordinary Shares at HKD5.99 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2483857827","media":"THOMSON REUTERS","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483857827?lang=en_us&edition=full_marsco","pubTime":"2024-11-14 18:55","pubTimestamp":1731581711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01530","BK1593","BK1161","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":0.0985},{"period":"1month","weight":0.5704},{"period":"3month","weight":0.7884},{"period":"6month","weight":0.688},{"period":"1year","weight":0.9002},{"period":"ytd","weight":0.7796}],"compareEarnings":[{"period":"1week","weight":-0.052},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.1684},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.4131},{"period":"ytd","weight":0.1707}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003645},{"month":2,"riseRate":0.5,"avgChangeRate":0.007788},{"month":3,"riseRate":0.8,"avgChangeRate":0.105791},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.015967},{"month":5,"riseRate":0.666667,"avgChangeRate":0.057469},{"month":6,"riseRate":0.777778,"avgChangeRate":0.012147},{"month":7,"riseRate":0,"avgChangeRate":-0.078897},{"month":8,"riseRate":0.4,"avgChangeRate":-0.006345},{"month":9,"riseRate":0.6,"avgChangeRate":0.027364},{"month":10,"riseRate":0.4,"avgChangeRate":-0.022784},{"month":11,"riseRate":0.7,"avgChangeRate":0.064392},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027233}],"exchange":"SEHK","name":"3SBIO","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 3SBIO(01530) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"3SBIO,01530,3SBIO股票,3SBIO股票老虎,3SBIO股票老虎国际,3SBIO行情,3SBIO股票行情,3SBIO股价,3SBIO股市,3SBIO股票价格,3SBIO股票交易,3SBIO股票购买,3SBIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"3SBIO(01530),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 3SBIO(01530) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}